Your browser doesn't support javascript.
loading
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Ferraldeschi, Roberta; Nava Rodrigues, Daniel; Riisnaes, Ruth; Miranda, Susana; Figueiredo, Ines; Rescigno, Pasquale; Ravi, Praful; Pezaro, Carmel; Omlin, Aurelius; Lorente, David; Zafeiriou, Zafeiris; Mateo, Joaquin; Altavilla, Amelia; Sideris, Spyridon; Bianchini, Diletta; Grist, Emily; Thway, Khin; Perez Lopez, Raquel; Tunariu, Nina; Parker, Chris; Dearnaley, David; Reid, Alison; Attard, Gerhardt; de Bono, Johann.
Afiliación
  • Ferraldeschi R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Nava Rodrigues D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Riisnaes R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Miranda S; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Figueiredo I; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Rescigno P; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Ravi P; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Pezaro C; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Omlin A; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Lorente D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Zafeiriou Z; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Mateo J; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Altavilla A; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Sideris S; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Bianchini D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Grist E; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Thway K; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Perez Lopez R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Tunariu N; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Parker C; Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Dearnaley D; Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Reid A; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • Attard G; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK.
  • de Bono J; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: Johann.de-Bono@icr.ac.uk.
Eur Urol ; 67(4): 795-802, 2015 Apr.
Article en En | MEDLINE | ID: mdl-25454616
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Supervivencia sin Enfermedad / Fosfohidrolasa PTEN / Neoplasias de la Próstata Resistentes a la Castración / Acetato de Abiraterona / Antineoplásicos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Eur Urol Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Supervivencia sin Enfermedad / Fosfohidrolasa PTEN / Neoplasias de la Próstata Resistentes a la Castración / Acetato de Abiraterona / Antineoplásicos Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Eur Urol Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido